Back to top
more

Haemonetics (HAE)

(Real Time Quote from BATS)

$84.68 USD

84.68
125,369

-1.37 (-1.59%)

Updated Jun 14, 2024 01:15 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (142 out of 249)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Abbott (ABT) Benefits From Innovation Amid FX Headwinds

by Zacks Equity Research

Abbott's (ABT) mAbxience collaboration is likely to help introduce cutting-edge medicines in the areas of oncology, women's health and respiratory diseases.

Teleflex (TFX) Enrolls First Patient in ACCESS-MANTA Registry

by Zacks Equity Research

Teleflex's (TFX) ACCESS-MANTA Registry is likely to examine the contemporary on-label use of the MANTA VCD.

Medtronic (MDT) Q2 Earnings Beat Estimates, 2024 View Up

by Zacks Equity Research

Medtronic (MDT) Q2 results reflect broad strength across businesses and geographies, benefiting from durable fundamentals.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.

Zimmer Biomet's (ZBH) Knee Sales Robust, Macro Woes Hurt

by Zacks Equity Research

Zimmer Biomet (ZBH) is working to strengthen its foothold in emerging markets that provide long-term opportunities for growth.

Boston Scientific (BSX) Closes the Relievant Medsystems Buyout

by Zacks Equity Research

Boston Scientific (BSX) expands the neuromodulation portfolio with the acquisition of Relievant Medsystems.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

STERIS' (STE) Healthcare segment continues to benefit from procedure volume recovery.

National Vision's (EYE) Market Expansion Aids, Inflation Ails

by Zacks Equity Research

National Vision (EYE) is expanding sales by the continued rollout of its remote medicine technology.

Myriad Genetics (MYGN) Expands Pharma Services With New Pact

by Zacks Equity Research

Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.

Medtronic's (MDT) Symplicity Spyral RDN System Gets FDA Boost

by Zacks Equity Research

Medtronic (MDT) receives the FDA approval for Symplicity blood pressure procedure for the treatment of hypertension.

Paragon 28 (FNA) BEAST Cortical Fibers Launch Boosts Biologics

by Zacks Equity Research

Paragon 28's (FNA) BEAST Cortical Fibers' advanced processing capability ensures the preservation of native bone morphogenic proteins and other growth factors crucial for bone formation.

Nemaura (NMRD) to Expand in UK With Metabolic Health Program

by Zacks Equity Research

The latest program leverages Nemaura's (NMRD) world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics.

Neogen's (NEOG) Innovation Aids, Currency Headwind Stays

by Zacks Equity Research

Neogen (NEOG) is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets.

Charles River (CRL) Widens CliniPrime GMP Suite With New Launch

by Zacks Equity Research

Charles River (CRL) brings CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing.

Paragon 28 (FNA) New Staple System Expands Ankle Device Line

by Zacks Equity Research

Paragon 28's (FNA) JAWS Great White Staple System is claimed to have 400 times greater fatigue life compared to competitors under similar load conditions.

Omnicell's (OMCL) Portfolio Expansion Aids Amid Macro Woes

by Zacks Equity Research

Omnicell (OMCL) accelerates its shift to cloud-based solutions and tech-enabled services through the launch of Inventory Optimization Service and Central Pharmacy Dispensing Services.

Here's Why You Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) due to its technology and innovative solutions.

Illumina (ILMN) Launches Initiative on Pathogen Sequencing

by Zacks Equity Research

Illumina (ILMN) introduces a new initiative to drive more equitable access to genomics globally.

HAE or SYK: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HAE vs. SYK: Which Stock Is the Better Value Option?

Prestige Consumer's (PBH) Brand Building, Innovation Aid Growth

by Zacks Equity Research

Prestige Consumer's (PBH) long-term brand-building efforts, efficient marketing, channel development and innovation help the company to continually hold a leading market share position.

QIAGEN (QGEN) Launches QIAcuity Kits and Software Update

by Zacks Equity Research

QIAGEN's (QGEN) new QIAcuity kits are likely to expand application areas and foster digital PCR adoption.

Here's Why Investors Should Buy Alcon (ALC) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about Alcon (ALC), backed by a competitive product portfolio and strong commercial execution.

IDEXX's (IDXX) Upcoming Launch to Detect Canine Leishmaniosis

by Zacks Equity Research

IDEXX (IDXX) expands the SNAP franchise with a comprehensive solution for detecting canine leishmaniosis.

Is Haemonetics (HAE) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business and momentum in ProCyte One expansion.